Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

David Miles; David Cameron; Igor Bondarenko; Lyudmila Manzyuk; Juan Carlos Alcedo; Roberto Ivan Lopez; Seock-ah Im; Jean-luc Canon; Yaroslav Shparyk; Denise A. Yardley; Norikazu Masuda; Jungsil Ro; Neelima Denduluri; Stanislas Hubeaux; Cheng Quah; Carlos Bais; Joyce O'shaughnessy

doi:10.1016/j.ejca.2016.09.024

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

David Miles, David Cameron, Igor Bondarenko, Lyudmila Manzyuk, Juan Carlos Alcedo, Roberto Ivan Lopez, Seock-ah Im, Jean-luc Canon, Yaroslav Shparyk, Denise A. Yardley, Norikazu Masuda, Jungsil Ro, Neelima Denduluri, Stanislas Hubeaux, Cheng Quah, Carlos Bais, Joyce O'shaughnessy

Research output: Contribution to journal › Article › peer-review

Original language	English
Journal	European Journal of Cancer
Early online date	4 Nov 2016
DOIs	https://doi.org/10.1016/j.ejca.2016.09.024
Publication status	E-pub ahead of print - 4 Nov 2016

Access to Document

10.1016/j.ejca.2016.09.024

http://linkinghub.elsevier.com/retrieve/pii/S0959804916324704

Cite this

Miles, D., Cameron, D., Bondarenko, I., Manzyuk, L., Alcedo, J. C., Lopez, R. I., Im, S., Canon, J., Shparyk, Y., Yardley, D. A., Masuda, N., Ro, J., Denduluri, N., Hubeaux, S., Quah, C., Bais, C., & O'shaughnessy, J. (2016). Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer. Advance online publication. https://doi.org/10.1016/j.ejca.2016.09.024

@article{42d907e320e6437f91ba2aeaaa62ea45,

title = "Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation",

author = "David Miles and David Cameron and Igor Bondarenko and Lyudmila Manzyuk and Alcedo, {Juan Carlos} and Lopez, {Roberto Ivan} and Seock-ah Im and Jean-luc Canon and Yaroslav Shparyk and Yardley, {Denise A.} and Norikazu Masuda and Jungsil Ro and Neelima Denduluri and Stanislas Hubeaux and Cheng Quah and Carlos Bais and Joyce O'shaughnessy",

year = "2016",

month = nov,

day = "4",

doi = "10.1016/j.ejca.2016.09.024",

language = "English",

journal = "European Journal of Cancer",

issn = "0959-8049",

publisher = "Pergamon Press",

}

Miles, D, Cameron, D, Bondarenko, I, Manzyuk, L, Alcedo, JC, Lopez, RI, Im, S, Canon, J, Shparyk, Y, Yardley, DA, Masuda, N, Ro, J, Denduluri, N, Hubeaux, S, Quah, C, Bais, C & O'shaughnessy, J 2016, 'Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation', European Journal of Cancer. https://doi.org/10.1016/j.ejca.2016.09.024

Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. / Miles, David; Cameron, David; Bondarenko, Igor et al.
In: European Journal of Cancer, 04.11.2016.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation

AU - Miles, David

AU - Cameron, David

AU - Bondarenko, Igor

AU - Manzyuk, Lyudmila

AU - Alcedo, Juan Carlos

AU - Lopez, Roberto Ivan

AU - Im, Seock-ah

AU - Canon, Jean-luc

AU - Shparyk, Yaroslav

AU - Yardley, Denise A.

AU - Masuda, Norikazu

AU - Ro, Jungsil

AU - Denduluri, Neelima

AU - Hubeaux, Stanislas

AU - Quah, Cheng

AU - Bais, Carlos

AU - O'shaughnessy, Joyce

PY - 2016/11/4

Y1 - 2016/11/4

U2 - 10.1016/j.ejca.2016.09.024

DO - 10.1016/j.ejca.2016.09.024

M3 - Article

SN - 0959-8049

JO - European Journal of Cancer

JF - European Journal of Cancer

ER -

Miles D, Cameron D, Bondarenko I, Manzyuk L, Alcedo JC, Lopez RI et al. Bevacizumab plus paclitaxel versus placebo plus paclitaxel as first-line therapy for HER2-negative metastatic breast cancer (MERiDiAN): A double-blind placebo-controlled randomised phase III trial with prospective biomarker evaluation. European Journal of Cancer. 2016 Nov 4. Epub 2016 Nov 4. doi: 10.1016/j.ejca.2016.09.024